Downloadable Slidesets

Share

Program Content

Activities

  • AML Without Targetable Tx
    Selecting Therapy for AML Without Predictive Biomarkers or Therapeutically Actionable Genomic or Molecular Alterations
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 17, 2021

    Expires: June 16, 2022

  • AML With Targetable Tx
    Selecting Therapy for AML With Predictive Biomarkers or Therapeutically Actionable Genomic or Molecular Alterations
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 17, 2021

    Expires: June 16, 2022

  • New Therapies in AML
    New and Novel Advances in AML Therapeutics
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 17, 2021

    Expires: June 16, 2022

  • <i>EP</i>: AML Expert Guidance
    ExpressPoints
    Exploring an Expanding AML Therapeutic Armamentarium: Expert Guidance to Optimize Outcomes
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 23, 2021

    Expires: June 22, 2022

Faculty

cover img faculity

Amir Fathi, MD

Assistant Professor of Medicine
Department of Medicine
Harvard Medical School
Division of Hematology/Oncology
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

cover img faculity

Daniel A. Pollyea, MD, MS

Professor of Medicine
Clinical Director of Leukemia Services
Associate Chief of Clinical Affairs
Robert H. Allen MD Chair in Hematology Research
Division of Hematology
University of Colorado School of Medicine
Aurora, Colorado

cover img faculity

Eunice S. Wang, MD

Chief, Leukemia and Benign Hematology Service
Professor of Oncology
Roswell Park Comprehensive Cancer Center
Buffalo, New York

Provided by

ProCE Banner

Provided by the National Comprehensive Cancer Network in collaboration with Clinical Care Options, LLC

Supporters

Supported by educational grants from

AbbVie Inc.

Astellas Pharma US

Pfizer, Inc.

Servier Pharmaceuticals